Immune-mediated rash or dermatitis occurred in 1.8% (34/ ... Europe and Asia. IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction ...

Immune-mediated rash or dermatitis occurred in 1.8% (34/1889 ... The safety and effectiveness of IMFINZI has not been established in pediatric patients. IMFINZI® (durvalumab), as a single ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers ...

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer Based on ADRIATIC Phase III trial results which showed a 27 ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...